CC
NVAX icon

Centiva Capital’s Novavax NVAX Stock Holding History

Centiva Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,959
Closed -$96.2K – 1966
2024
Q4 		$96.2K Buy
+11,959
New +$115K ﹤0.01% 1498
2023
Q1 		– Sell
-67
Closed -$689 – 1741
2022
Q4 		$689 Sell
67
-41,686
-100% -$736K ﹤0.01% 1324
2022
Q3 		$760K Sell
41,753
-6,344
-13% -$275K 0.01% 731
2022
Q2 		$2.47M Buy
48,097
+7,487
+18% +$388K 0.06% 308
2022
Q1 		$2.99M Buy
40,610
+14,632
+56% +$1.3M 0.06% 302
2021
Q4 		$3.72M Buy
25,978
+13,477
+108% +$2.32M 0.08% 232
2021
Q3 		$2.59M Buy
12,501
+291
+2% +$64.1K 0.16% 133
2021
Q2 		$2.59M Buy
12,210
+10,940
+861% +$2M 0.06% 266
2021
Q1 		$230K Buy
+1,270
New +$253K 0.01% 917

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's NVAX Position: Q1 2025 in Review

Centiva Capital sold out of Novavax (NVAX) in Q1 2025, closing a stake of 11,959 shares — an estimated $96.2K sold.

Centiva Capital first reported a position in NVAX in Q1 2021 and held it in 9 quarters. The position peaked at $3.72M in Q4 2021. 246 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Centiva Capital reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 11,959 Novavax shares in Q1 2025, an estimated $96.2K.
  • Centiva Capital first reported a position in Novavax in Q1 2021 and held it in 9 quarters.
  • Centiva Capital's Novavax position peaked at $3.72M in Q4 2021.
  • 246 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.